Monday, May 27, 2024

Your $200 account credit is about to expire

Hello there - 

You have just two more days left to get your 30-day trial to MarketBeat All Access for free. This link will expire, so don't put this off.

If you register for MarketBeat All Access in the next two days, you can get your first month for free. If you want to continue your subscription after your 30-day trial, you will receive a $200 account credit toward your subscription. If you do not want to continue your subscription after your trial, cancel your subscription, and you won't be billed.

Click Here to Claim Your Free 30-Day Subscription

Join the dozens of other savvy investors who have taken advantage of this offer in the last few days. Here's what a few of them have been saying about MarketBeat:

"I use MarketBeat.com every day that the market is open to provide me with the most up to date financial data allowing me to support my investing decisions. There are multiple ways that you can use this resource including the ability to personalize areas of interest and specific stock lists. I have tested several financial service companies and this one is the best by far" - Ronald S.
 
"MarketBeat offers astute analysis of stocks and how they relate to the market as a whole. Their reports are concise and to the point. MarketBeat stands out as highly ethical, subjecting stocks and the broader market to the cold hard light of meticulous research. This allows me a high degree of confidence in their recommendations." -Dorothy L.
 
With your premium subscription, you will receive:
  • Personalized News and Ratings - Get news, price metrics, ratings, earnings, dividends, and insider trades for stocks that you add to your stocks list.
  • Broker Performance and Accuracy Ratings - Each analyst recommendation is paired with an accuracy rating so that you know which analyst ratings changes you should pay attention to and which you can safely ignore.
  • Follow the Market with Ease - You will receive a full rundown of each day's analysts' ratings changes, earnings announcements, dividend declarations, insider trades, and top news headlines.
  • Early Delivery - Your daily newsletter will be delivered a full 30 minutes before the New York Stock Exchange opens. You'll also receive our closing bell update that contains midday news and ratings changes. 
  • Breaking News Alerts - When breaking news happens for one of your stocks, we'll send you an email or SMS alert to let you know what's happening.
  • Portfolio Monitoring Tools - Your MarketBeat subscription allows you to follow an unlimited number of stocks in My MarketBeat, our portfolio monitoring tool that provides you with up-to-the-minute headlines, prices, analyst recommendations, and more. 
  • Excel Export - Receive your newsletter in an easy-to-copy table format and export each day's ratings, earnings, dividends, and insider trading data to Microsoft Excel or CSV format.
  • Brokerage Syncing - You’ll have the increased ability to track real-time performance and analytics for the stocks that matter most to you. Create a watchlist securely linked to your brokerage accounts for automatic updates whenever you buy or sell stocks.
Click Here to Subscribe to MarketBeat All Access (Free For 30 Days!)

Rebecca McKeever
MarketBeat
 
P.S. If you have any questions about MarketBeat All Access, just hit reply to this email. Our South Dakota-based support team is standing by to answer your questions. Andrew, Maureen, Wendy, and Liz would love to hear from you.

 
 
 
 
 
 
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
 
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
 
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
 
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
 
Today's Bonus Content: Explore Top Picks for Investors in 2024! (Click to Opt-in)

No comments:

Post a Comment

What Elon got wrong about the CR

Presented by The Campaign for Sustainable Rx Pricing: An evening recap of the action on Capitol Hill and preview of ...